Prognosis depends on the appropriateness of protocols. Expected EFS has been mentioned with each category of treatment in the preceding discussion. Table 16-10
Table 16-10. Factors Associated with Favorable and Unfavorable Prognosis"
Stages I and II: Head and neck (nonparameningeal) Peripheral nodes
Abdominal site: 80% or greater 2-year survival (recurrence after 2 years rare) Unfavorable prognosis
Stage of disease: Stage III or IV
Stage IV with CNS involvement: worst prognosis Site of disease:
Parameningeal stage II
All stages of extranodal, extralymphatic NHL in head and neck area (sinus, jaw, orbit, scalp)
Presence of pleural effusion in stage III small noncleaved cell lymphoma Incomplete initial remission within 2 months Soluble IL-2 R level
>1000 U/mL LDH level
aAll of the above variables essentially reflect tumor burden—the higher the burden the worse the prognosis. IL-2R is a more specific marker of lymphoid malignancy than LDH and can be used as a marker to differentiate small round cell tumors of lymphoid origin from nonlymphoid origin.
lists clinical and biological factors associated with favorable and unfavorable prognosis.
Was this article helpful?